Skip Navigation and Go To Content

Clinical Trials Resource Center

Ongoing Trials at UTHealth

DERMATOLOGY

LIVER

HEART & VASCULAR

HEMODIALYSIS

  • Heparin-bonded versus Non-heparin-bonded Polytetrafluroethylene Hemodialysis Access Grafts
    Coordinator Name: Samuel Leake
    E-mail: Samuel.S.Leake@uth.tmc.edu 
    Phone: 713-486-5120
    Principal Investigator: Kristofer Charlton-Ouw, MD
    for more information - clinicaltrials.gov

HIV

HYPERTENSION

  • Determination of Genetics in Childhood Onset Hypertension 
    Coordinator Name: Josephine Turner
    Phone: 713-704-4137
    Email: Josephine.Turner@uth.tmc.edu
    Coordinator Name: Cary Warner
    Phone Number: 713-704-3743
    Principal Investigator: Syed Hashmi, MD, MPH, PhD

NEPHROLOGY

  • A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Safety and Efficacy of CCX168 (Avacopan) in Patients with Anti-Neutrophil Cytoplasmic Antibody (ANCA)- Associated Vasculitis Treated Concomitantly with Rituximab or Cyclophosphamide/Azathioprine
    Principal Investigator: Dia R. Waguespack, MD
    Study Coordinator: Iram Abbasi
    Email: RenalResearch@uth.tmc.edu
    Phone: 713-500-6820
    Main Inclusion Criteria: Aged at least 18 years, with newly-diagnosed or relapsed AAV where treatment with Cyclophosphamide or rituximab is needed
  • A phase III, randomised, open-label, comparative safety and efficacy trial of intravenous iron isomaltoside (Monofer®) and iron sucrose in subjects with iron deficiency anemia and non-dialysis-dependent chronic kidney disease
    Principal Investigator: Dia R. Waguespack, MD
    Study Coordinator: Iram Abbasi
    Email: RenalResearch@uth.tmc.edu
    Phone: 713-500-6820
    Main Inclusion Criteria: >18 years of age
  • A Study to Evaluate the Effect of Dapagliflozin on Renal Outcomes and Cardiovascular Mortality in Patients with Chronic Kidney Disease
    Principal Investigator: Dia R. Waguespack, MD
    Study Coordinator: Iram Abbasi
    Email: RenalResearch@uth.tmc.edu
    Phone: 713-500-6820
    Main Inclusion Criteria: >18 years of age
  • A Randomized, Controlled Double-blind Study Comparing the Efficacy and Safety of Orelvo (voclosporin) (23.7 mg Twice Daily) with Placebo in Achieving Renal Response in Subjects with Active Lupus Nephritis
    Principal Investigator: Dia R. Waguespack, MD
    Study Coordinator: Iram Abbasi
    Email: RenalResearch@uth.tmc.edu
    Phone: 713-500-6820
    Main Inclusion Criteria: 18 to 75 years of age
  • Pathway Exploration and Analysis in Renal Lupus (PEARL) – Phase 2
    Principal Investigator: Dia R. Waguespack, MD
    Study Coordinator: Iram Abbasi
    Email: RenalResearch@uth.tmc.edu
    Phone: 713-500-6820
    Main Inclusion Criteria: >18 years of age

NEUROLOGY

  • Aseptic Meningoencephalitis in Adults 
    Coordinator Name: Monika Ruscheinsky 
    E-mail: monika.ruscheinsky@uth.tmc.edu   
    Phone: 713-704-0825 
    Principal Investigator: Rodrigo Hasbun, MD, MPH
  • Relapsing Remitting Multiple Sclerosis Study
    EVOLVE II ALK8700-A302: A Phase 3 Study in Subjects with Relapsing Remitting Multiple Sclerosis to Evaluate the Tolerability of ALKS 8700 and Dimethyl Fumarate
    Study Coordinator: Jim Jemelka
    E-mail: James.R.Jemelka@uth.tmc.edu
    Phone: 713-500-7045
    Principal Investigator: Flavia M. Nelson, MD

    Target Population: People with relapsing remitting multiple sclerosis

  • Multiple Sclerosis Study
    NARCRMS (North American Registry for Care and Registry for Multiple Sclerosis): Towards the development of a National Longitudinal Database in Multiple Sclerosis. Under the auspices of the Consortium of MS Centers (CMSC)
    Study Coordinator: Jim Jemelka
    E-mail: James.R.Jemelka@uth.tmc.edu
    Phone: 713-500-7045
    Principal Investigator: Flavia M. Nelson, MD

    Target Population: People with multiple sclerosis within the first 10 years of diagnosis
  • Relapsing Multiple Sclerosis Study
    LEM-COG Trial: A 24-Month Observational Study to Evaluate Neurocognitive Function and Safety in Patients with Relapsing Multiple Sclerosis Who are Initiating LEMTRADA® (Alemtuzamab) Treatment in Routine Clinical Practice
    Study Coordinator: Jim Jemelka
    E-mail: James.R.Jemelka@uth.tmc.edu
    Phone: 713-500-7045
    Principal Investigator: John Lincoln, MD, PhD

    Target Population: People with relapsing multiple sclerosis who are initiating Lemtrada® (alemtuzamab) treatment in routine clinical practice

  • Multiple Sclerosis Study
    Lower extremity exoskeleton to promote walking in persons with multiple sclerosis
    Study Coordinator: Jim Jemelka
    E-mail: James.R.Jemelka@uth.tmc.edu
    Phone: 713-500-7045
    Principal Investigators: Shuo-Hsiu (James) Chang, PT, PhD; John Lincoln, MD, PhD

    Target Population: People with multiple sclerosis who are willing to complete 5 training sessions each week for 3 weeks at the Texas Institute of Rehabilitation and Research (TIRR) at the Texas Medical Center

PEDIATRIC SURGERY

PSYCHIATRY

  • Searching for Endophenotypes of Bipolar Disorder
    Study Overview: A sibling study for same-sex patients within 10 years of each other, where one sibling has been diagnosed with bipolar disorder.
    E-mail: utmooddisorders@uth.tmc.edu
    Phone: 713-486-2627
    Principal Investigator: Jair C. Soares, MD
  • Deep Brain Stimulation (DBS) Therapy for Treatment Resistant Depression
    Study overview: In DBS for TRD a neurosurgeon implants a small electrode in the brain that delivers electrical stimulation to an area of the brain. The purpose of the study is to obtain a preliminary indication of the feasibility, safety and efficacy of DBS in the new site, supero-lateral branch of the medial forebrain bundle (slMFB).
    E-mail: utmooddisorders@uth.tmc.edu
    Phone: 713-486-2627
    Principal Investigator: Jair C. Soares, MD
  • Pediatric Bipolar Registry
    Study overview: A study to follow the outcomes of children with bipolar disorder, DMDD, or who have a parent that has been diagnosed with bipolar disorder.
    E-mail: utmooddisorders@uth.tmc.edu
    Phone: 713-486-2627
    Principal Investigator: Jair C. Soares, MD  
  • A Study to Evaluate the Effect of ALKS 3831 Compared to Olanzapine on Body Weight in Young Adults with Schizophrenia, Schizophreniform, or Bipolar I Disorder Who are Early in Their Illness
    Study overview: Olanzapine is an atypical antipsychotic that has been approved by a number of different countries to treat schizophrenia and bipolar disorder. A common side effect of olanzapine is that it causes weight gain. ALKS 3831 is designed to reduce some of olanzapine's weight gain. The present study will see if there is a reduction in weight gain when ALKS 3831 is given to adolescents and young adults.
    E-mail: utmooddisorders@uth.tmc.edu
    Phone: 713-486-2627
    Principal Investigator: Jair C. Soares, MD
  • A Double-blind, Placebo- and Active-Controlled Evaluation of the Safety and Efficacy of Levomilnacipran ER in Adolescent Patients with Major Depressive Disorder
    Study overview: An 26 week, placebo-controlled, antidepressant therapy study of Levomilnacipran, brand name Fetzima, a SNRI that has proven effective in treatment of MDD in adults.
    E-mail: utmooddisorders@uth.tmc.edu
    Phone: 713-486-2627
    Principal Investigator: Jair C. Soares, MD
  • A Phase 3, Multicenter, Four-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Efficacy And Safety Trial Of Flexible Doses Of Oral Ziprasidone In Children And Adolescents With Bipolar I Disorder (Current Or Most Recent Episode Manic)
    Study overview: Ziprasidone, brand name Geodon, is an atypical antipsychotic that has demonstrated its effectiveness for the treatment of schizophrenia in adults, as well as the treatment of Bipolar Disorder in adults with manic symptoms. The purpose of this trial is to test the safety, tolerability and efficacy of Ziprasidone compared with placebo in the treatment of children and adolescents with Bipolar Disorder.
    E-mail: utmooddisorders@uth.tmc.edu
    Phone: 713-486-2627
    Principal Investigator: Jair C. Soares, MD
  • Effect of Systemic Inflammation on Emotion and Cognition in Patients with Mood Disorder - A Vaccine Study
    Study overview: A study testing inflammatory response to typhoid injections in adults.
    E-mail: utmooddisorders@uth.tmc.edu
    Phone: 713-486-2627
    Principal Investigator: Sudhakar Selvaraj, MD  

PULMONARY

REPRODUCTIVE

 

RHEUMATOLOGY

SCLERODERMA

SLEEP

SUBSTANCE ABUSE

  • Cocaine Use Treatment Research Studies
    Cognitive-enhancing DA Medications for Cocaine Dependence
    Coordinator: Jessica Vincent
    E-mail: Jessica.N.Vincent@uth.tmc.edu
    Phone: 713-486-2803
    Principal Investigator: Joy M. Schmitz, PhD
  • PTSD & Substance Use Treatment Study
    Trial of a Novel Treatment for Posttraumatic Stress and Substance Dependence
    Coordinator: Jessica Vincent
    E-mail: Jessica.N.Vincent@uth.tmc.edu
    Phone: 713-486-2803
    Principal Investigator: Anka Vujanovic, PhD

TRAUMA

WEIGHT LOSS

ADDITIONAL RESOURCES

CLINICAL RESEARCH UNITS (CRU) | BERD | REDCap
COMMITTEE FOR THE PROTECTION OF HUMAN SUBJECTS | ANIMAL RESEARCH | ENVIRONMENTAL HEALTH & SAFETY | CORE LABORATORIES | SPONSORED PROJECTS TECHNOLOGY MANAGEMENT
OFFICE OF RESEARCH 

Center for Clinical and Translational Sciences

Clinical Trials Resource Center (CTRC)
7000 Fannin Street, Suite 795

Houston, Texas 77030
phone 713-500-3622
fax 713-500-0334
clinicaltrials@uth.tmc.edu

last modified October, 2013
Copyright © 2012
How can we improve this site?